Figure 7. Nilotinib is unable to prevent MPTP-induced parkin phosphorylation and accumulation of AIMP2, but reduces PARIS in the ventral midbrain of MPTP-treated mice.

(a) Immunoblots of parkin immunoprecipitation samples from C57/BL6 mice treated with saline, MPTP only, MPTP with nilotinib (25 mg/kg body wt), or nilotinib alone (25 mg/kg body wt). Immunoblotting with an anti-phosphotyrosine antibody shows tyrosine-phosphorylated parkin and an anti-parkin antibody shows immunoprecipitated parkin. Brain lysates were immunoblotted with anti-AIMP2 and anti-PARIS antibodies to monitor their levels with β-actin serving as a loading control. (b) Normalized levels of tyrosine-phosphorylated parkin (p-parkin), AIMP2, and PARIS are indicated. The Error bars represent the mean ± SEM (n = 4 mice per group). Two-way ANOVA was used to test significance and followed with post-hoc Bonferroni test to compare with the multiple groups. ** p<0.001 for MPTP with compared to the control group, ##p<0.001 for Nil plus MPTP compared to the MPTP group. All experiments were repeated three times and representative images of the immunoblots are shown. Full length blots are presented in the supplementary Figure S2.